Biomed/Biotech Special Interest Group  

6:00 – 6:20 PM – Networking; Pizza/drink 

6:20 – 8:45 PM – Program 

8:45 – 9:00 PM – Door-prizes drawing; Networking

$5: non-ASQ members to cover pizza/drink cost; 

Free: ASQ members, veterans, senior citizens, past speakers, teachers, students, interns, residents, postdocs, FDA Commissioner’s Fellows, MJ-DC members, NTUAADC members, CAPA members, CKUADC members, CCACC volunteers/employees, FAPAC members, CBA members, AAGEN members, Commissioned Corp officers, and current job-seekers. 

Location: Kelly’s Deli Conference Center, 7519 Standish Place, Rockville (Derwood, for GPS users), MD 20855

Registration Deadline: Please register by Thursday noon, August 28, 2014.  

Question: Please contact Dr. C.J. George Chang, Chair of Biomed/Biotech SIG, ASQ509; gchang2008@yahoo.com or 240-793-8425 (cell).

Driving directions: By Cars: From I-270 (N or S bound): Take Exit 9A and exit from the FIRST right exit; turn left (east) onto Shady Grove Dr.; turn right (south) onto Rockville Pike (Route 355); turn left (east) onto East Gude Dr.; turn left (north) immediately onto Crabb’s Branch Dr.; turn left (west) immediately onto Standish Place. The first building on your right side is 7519 Standish Place; open parking). The venue is on the first floor with its entrance opposite to the left side of building main entrance. By Metro trains: Off from Red Line Shady Grove Station, and take RideOn Route 59 TOWARD ROCKVILLE and get off from “Calhoun Place” stop. Standish Place is next to the Bus stop. Our venue is within 2 min of walking distance from the stop.

The US Health Care Reform has its huge impact on behavior care delivery and research agenda.  The Patient Protection and Affordable Care Act (2010) and the Mental Health Parity and Addiction Equity Act (2008) expand substance use disorder (SUD) care services in the US into general medical settings.  Addiction is a chronic brain disease with consequences that remain problematic years after discontinuation of use.  The treatment of SUD must adapt to a chronic care model offered in an integrated care system that screens for at-risk patients and includes services needed to prevent relapses.  The partnering of the health care system with substance abuse treatment programs could dramatically expand the benefits of prevention and treatment of SUD.  Expanding roles of health information technology is essential to the success of a chronic care model.

These changes brought great opportunities and considerable challenges to the SUD research communities.  NIDA must embrace these opportunities and address the challenges.

Dr. Betty Tai is the Director of Center for the Clinical Trials Network, NIDA, NIH, US HHS.  For the past 14 years, Dr. Tai has been the founding leader of NIDA’s first and largest Clinical Trials Network.  Utilizing her expertise in clinical psychopharmacology, Dr. Tai leads a network of academic institutions in partnership with a wide range of drug treatment providers to bridge the gap between research and practice by rapidly translating research into patient care and by elevating the standards of drug abuse treatment through practices that are science based.  Under her leadership, the CTN has been recognized, nationally and internationally, for its important contributions to the improvement of drug abuse treatment. 

Dr. Tai is also leading NIDA’s efforts in its Electronic Health Records (HER) Development/Implementation Task Force representing NIDA throughout government and the private sector in a National effort to establish consensus on data elements and ensuring that balanced policies are in place to protect patient privacy as drug abuse treatment is integrated into mainstream medicine.  The gains she has achieved in a short period of time to ensure that drug abuse is part of the EHR enterprise have been impressive.  She is now the lead of NIDA’s taskforce on the development of chronic care model for drug treatment to bring treatment into general medical settings.

Among her many awards, Dr. Tai, is the recipient of American Psychological Association’s Research Service Award and the J. Michael Morrison Award from the College on Problems of drug Dependence (CPPD) recognizing her outstanding contributions in the scientific administration of drug abuse treatment.